Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The fallout from the F.D.A.’s rejection of a new treatment for PTSD worries researchers and experts who fear other ...

Minutes joined U.S. veterans with PTSD as they attend a week-long psychedelic retreat in Mexico. Nearly a year later, most of ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

Entering the field of psychedelic therapy requires patience, dedication to learning, and careful attention to legal and ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

Much of the association between trauma and suicide risk among university students can be explained by shame, a new study ...

The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States.

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...